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ffects  of  ethinylestradiol–cyproterone  acetate
s. pioglitazone–ﬂutamide–metformin  on  plasma
GF21  levels  in  adolescent  girls  with  androgen
xcess
.  Introduction
Fibroblast growth factor 21 (FGF21) is a hormonal factor with
otentially antidiabetic properties. In rodent models of obesity
nd type 2 diabetes (T2D), FGF21 improved glucose and lipid
evels, and reduced body weight [1]. In a pilot study of obese peo-
le with T2D, short-term administration of an FGF21 analogue
howed comparable effects [2]. In contrast, most clinical stud-
es have reported high FGF21 levels in obese, insulin-resistant
atients with T2D; this paradox has been attributed to a state of
GF21 resistance in obesity [3].
Hyperinsulinaemic androgen excess (HAE) is the most com-
on cause of hirsutism and menstrual irregularity in girls and
oung women, and is associated with comorbidities in adult-
ood, including T2D [4]. Yet, only a few studies have assessed
irculating FGF21 levels in women with HAE and found contra-
ictory results; such studies included mostly obese women and
ere cross-sectional in design [5–7].
It has been reported that, in adolescents with HAE, insulin
ensitization compared with oestrogen–progestogen contracep-
ion (OC) exerts greater beneficial effects on cardiometabolic
isk markers on and off intervention. Our aim was to study
hether these benefits are underscored by divergent FGF21
rofiles. To this end, the present study longitudinally assessed
GF21 levels in a subset of girls with HAE.
.  Subjects  and  methods
.1.  Study  population  and  design
The study population consisted of 25 non-obese adolescent
irls with HAE [mean age: 16 years; body mass index (BMI):
3 kg/m2] who were included in a randomized, open-label study
o compare the effects of OC with ethinylestradiol–cyproterone
cetate [EE–CA; 35 g of EE plus 2 mg of CA for 21 days,
ollowed by placebo for 7 days; Bayer Schering Pharma AG,Please cite this article in press as: Díaz M, et al. Effects of ethinylestradiol–
FGF21 levels in adolescent girls with androgen excess. Diabetes Metab (2
erlin, Germany] with the effects of a low-dose combination
f pioglitazone 7.5 mg/day, flutamide 62.5 mg/day and met-
ormin 850 mg/day (PioFluMet). The study was registered as
SRCTN45546616, and lasted for 24 months (18 months of
i
a
p
(
http://dx.doi.org/10.1016/j.diabet.2015.10.004
262-3636/© 2015 Elsevier Masson SAS. All rights reserved.letter
reatment followed by 6 months of no treatment) [4,7]. The
resent report includes only those girls with complete longitu-
inal data whose serum samples remained sufficiently abundant
o measure FGF21 at each study time point (∼  74% of the initial
tudy population: n  = 14 in the EE–CA subgroup; n  = 11 in the
ioFluMet subgroup).
.2.  Assessments
Clinical and endocrine–metabolic variables, body composi-
ion and abdominal fat partitioning were assessed as described
lsewhere [4,8]. Circulating FGF21 levels were determined
sing a specific non-cross-reactive enzyme-linked immunosor-
ent assay (ELISA; BioVendor Laboratory Medicine, Brno,
zech Republic); the detection limit was 4.8 pg/mL, and the
ntra- and interassay coefficients of variation were 3.5% and
.7%, respectively.
.3.  Statistical  analyses
These were performed with SPSS version 12.0 soft-
are (SPSS, Chicago, IL, USA). Results are expressed as
eans ±  SEM. Results with a non-Gaussian distribution were
og-transformed before analysis. Comparisons within and
etween groups at each time point were performed using a gen-
ral linear model. To assess the effects of treatment and time
imultaneously on FGF21 levels, two-way analysis of variance
ANOVA) was performed. P  < 0.05 was considered statistically
ignificant.
.  Results
Both treatments had comparable effects on measures of
ndrogen excess, but they had divergent effects on car-
iometabolic risk markers and body composition: PioFluMet
dministration was followed by more favourable on-treatment
nd post-treatment outcomes, as reported (see supplementary
able for differences in selected variables) [8].
FGF21 levels in HAE girls were comparable to those in age-
nd BMI-matched controls at baseline (Fig. 1, Table S1). After
8 months of treatment, FGF21 concentrations increased onlycyproterone acetate vs. pioglitazone–flutamide–metformin on plasma
015), http://dx.doi.org/10.1016/j.diabet.2015.10.004
n the EE–CA group, and remained elevated even after ther-
py discontinuation (P  = 0.02 between subgroups at both time
oints; Fig. 1). Treatment explained 11% of FGF21 variability
P = 0.04), while time explained only 2.4% (P  = 0.56).
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Fig. 1. Longitudinal fibroblast growth factor 21 (FGF21) concentra-
tions (means ± SEM) in adolescent girls with hyperinsulinaemic androgen
excess who were randomized to receive either an oral contracep-
tive [ethinylestradiol–cyproterone acetate (EE–CA); n = 14] or a low-dose
insulin-sensitizing treatment (PioFluMet; n = 11), comprising pioglitazone
(7.5 mg/day), flutamide (62.5 mg/day) and metformin (850 mg/day) for
18 months, with no treatment between 18–24 months. The upper and lower lim-
its of the grey zone correspond to a Z score of +1 and –1, respectively, in healthy
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control girls (age: 16.4 ± 0.4 years; BMI: 22.1 ± 0.2 kg/m ; n = 15). FGF21
ncreased significantly in the EE–CA group at 18 and 24 months. *P = 0.02
etween subgroups at 18 and 24 months (by two-sided t-test).
Initially, FGF21 correlated inversely with BMI and fat dis-
ribution in all patients (Table 1). At 18 and/or 24 months
f treatment, FGF21 was positively associated with meas-
res of insulin resistance, triglycerides and intrahepatic fat,
nd negatively associated with high-density lipoprotein (HDL)
holesterol and high-molecular-weight adiponectin (HMW-
dip) in the EE–CA subgroup. In the PioFluMet subgroup,
GF21 showed an inverse relationship with BMI and intrahep-
tic fat, and was positively correlated with HMW-adip (Table 1).
Also, in the PioFluMet girls, changes in FGF21 levels
etween 0 and 18 months were negatively correlated with
hanges in insulin resistance measures and intrahepatic fat,
nd positively correlated with changes in HMW-adip levels.
n contrast, in the EE–CA subgroup, FGF21 changes corre-
ated positively with glucose and intrahepatic fat changes, and
egatively with BMI and low-density lipoprotein (LDL) choles-
erol changes. These correlations remained significant only for
easures of insulin resistance (PioFluMet subgroup) and glu-
ose (EE–CA subgroup) on analyses performed between 0 and
4 months (Table 1).
.  Discussion
To our knowledge, this is the first longitudinal study com-
aring the effects of OC vs. insulin sensitization on circulating
GF21 concentrations in non-obese adolescents with HAE. Our
resent findings reveal that OC administration is followed by
ugmented FGF21 levels that persisted even after therapy with-
rawal.Please cite this article in press as: Díaz M, et al. Effects of ethinylestradiol–
FGF21 levels in adolescent girls with androgen excess. Diabetes Metab (2
FGF21 levels were within normal limits in all of our study
articipants at baseline and showed an inverse correlation with
easures of adiposity. Thus, in non-obese glucose-tolerant indi-
iduals, FGF21 may act as a metabolic modulator, as reported
d
O
a
abolism xxx (2015) xxx–xxx
n experimental studies [1]. In contrast, in overweight and
bese subjects with metabolic dysfunction and/or diabetes, high
ndogenous FGF21 concentrations fail to exert such benefits,
eading to a state of FGF21 resistance as a result of reduced
xpression of beta-Klotho co-receptors in metabolically key
rgans, including adipose tissue [9,10]. These effects appear to
e independent of the presence of HAE [7].
After 18 months of treatment, FGF21 concentrations
ncreased only in the EE–CA subgroup, and were associated
ith measures of insulin resistance, lipids, HMW-adip and intra-
epatic fat on and/or off therapy, but not with androgen levels,
hich is in agreement with previous reports [7]. The increase in
GF21 persisted off treatment together with more insulin resis-
ance and a less favourable cardiometabolic profile [4,8]. This
s in line with prospective studies showing that FGF21 inde-
endently predicts progression to the metabolic syndrome in
atients with metabolic dysfunction, such as those with obesity
nd impaired glucose homoeostasis [9–11].
Our findings have also revealed that FGF21 is a sensitive
arker that increases in response to any drift in either glu-
ose or lipid homeostasis in non-obese girls. The increase in
GF21 levels following EE–CA treatment could be a mecha-
ism to counteract the potentially negative effects of EE–CA
n intrahepatic fat and metabolic markers. Interestingly, FGF21
oncentrations remained unchanged in the PioFluMet subgroup
hether on or off treatment and in parallel with sustained
mprovements in cardiometabolic markers.
The effects of pioglitazone and metformin on circulating
GF21 levels remain controversial, although there is agree-
ent that both agents induce FGF21 expression in cultures of
at and human hepatocytes [12,13]. The effects of metformin
ppear to be mediated through AMPK activation [12], whereas
hose of pioglitazone might be exerted through peroxisome
roliferator-activated receptor gamma (PPAR) stimulation
13]. However, pioglitazone at the low doses used in our present
tudy is an inhibitor of cyclin-dependent kinase 5-mediated
hosphorylation of PPAR  rather than a PPAR  activator
4].
The few studies performed so far in hyperandrogenic patients
ere cross-sectional and included mostly obese women – not
dolescents – and used less restrictive inclusion criteria [5–7];
hus, the results may not be comparable.
Limitations of the present study include the relatively short
ollow-up period off therapy, the potential non-applicability of
ts conclusions to glucose-intolerant, diabetic and/or obese girls
ith HAE, and the fact that only the effects of EE–CA were
ssessed, which means the impact of other OC combinations
emain to be elucidated. The strengths include its longitudi-
al design, the rather homogeneous study population and the
ssessment of two interventions with divergent effects on car-
iometabolic health.
In conclusion, this report for the first time investigated FGF21
irculating levels in non-obese girls with HAE. The longitudinal
esign of the study allowed detection of the divergent effects of
C and insulin sensitization on serum FGF21 concentrations,cyproterone acetate vs. pioglitazone–flutamide–metformin on plasma
015), http://dx.doi.org/10.1016/j.diabet.2015.10.004
nd revealed that higher FGF21 levels in young girls with HAE
re linked to poorer endocrine–metabolic status.
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Table 1
Correlations between FGF21 and clinical, endocrine-metabolic and imaging parameters initially and during interventions with either ethinylestradiol-cyproterone
acetate (EE-CA) or low-dose pioglitazone + lutamide + metformin (PioFluMet) in girls with hyperinsulinaemic androgen excess.
Baseline (n = 25) 18 months  0–18 months
PioFluMet (n = 11) EE–CA (n = 14) PioFluMet (n = 11) EE–CA (n = 14)
r P r P r P r P r P
Body mass index –0.470 0.019 –0.786 0.007 0.249 0.390 0.194 0.568 –0.565 0.044
Glucose –0.158 0.449 –0.592 0.055 0.029 0.921 –0.851 0.015 0.573 0.032
Insulin –0.130 0.540 –0.356 0.283 0.397 0.160 –0.708 0.049 –0.153 0.619
HOMA-IR –0.360 0.075 –0.419 0.199 0.378 0.182 0.301 0.431 –0.075 0.797
AT-IR –0.214 0.315 –0.842 0.002 0.655 0.015 –0.691 0.039 –0.532 0.075
HDL cholesterol –0.020 0.924 0.385 0.242 –0.712 0.006 –0.208 0.564 –0.300 0.297
LDL cholesterol 0.217 0.297 0.106 0.757 –0.104 0.725 0.487 0.154 –0.563 0.034
Triglycerides 0.058 0.781 –0.067 0.845 0.548 0.04 –0.156 0.666 0.020 0.948
HMW-adip 0.042 0.844 0.701 0.024 –0.254 0.380 0.741 0.022 –0.239 0.454
Abdominal fata –0.682 0.0003 –0.338 0.308 0.134 0.649 –0.803 0.009 –0.223 0.464
Subcutaneous fatb –0.431 0.036 –0.456 0.159 0.077 0.794 0.066 0.847 –0.166 0.571
Visceral fatb –0.603 0.001 –0.615 0.058 0.169 0.563 –0.286 0.395 –0.345 0.228
Intrahepatic fatb –0.046 0.829 –0.244 0469 0.694 0.008 –0.711 0.032 0.613 0.034
24 months  0–24 months
PioFluMet (n = 11) EE–CA (n = 14) PioFluMet (n = 11) EE–CA (n = 14)
r P r P r P r P
Body mass index –0.628 0.038 0.093 0.749 –0.502 0.116 –0.204 0.484
Glucose 0.032 0.925 –0.228 0.434 –0.047 0.890 0.601 0.029
Insulin 0.446 0.196 0.627 0.022 –0.252 0.454 –0.276 0.340
HOMA-IR 0.471 0.169 0.587 0.035 –0.342 0.303 –0.232 0.426
AT-IR 0.114 0.739 0.125 0.671 –0.685 0.042 –0.181 0.537
HDL cholesterol 0.470 0.145 –0.582 0.037 0.381 0.247 –0.414 0.141
LDL cholesterol 0.219 0.517 –0.064 0.827 –0.194 0.591 0.211 0.468
Triglycerides –0.171 0.615 0.119 0.685 –0.109 0.765 0.221 0.469
HMW-adip 0.347 0.295 –0.660 0.038 0.523 0.149 –0.373 0.209
Abdominal fata –0.310 0.353 0.143 0.640 –0.200 0.555 –0.210 0.491
Subcutaneous fatb –0.265 0.430 –0.252 0.455 0.296 0.376 0.153 0.601
Visceral fatb –0.321 0.336 0.277 0.360 –0.221 0.513 –0.189 0.535
Intrahepatic fatb –0.661 0.027 0.222 0.445 0.145 0.671 –0.218 0.453
HOMA-IR: homoeostasis model assessment for insulin resistance; AT-IR: adipose tissue insulin-resistance index (serum free fatty acids x fasting insulin; Lomonaco
et al. [14]); HDL/LDL: high-density/low-density lipoprotein; HMW-adip: high-molecular-weight adiponectin.
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isclosure  of  interest
The authors declare that they have no competing interest.
cknowledgements
M.D. and L.I. are clinical investigators for CIBERDEM
Centro de  Investigación  Biomédica  en  Red  de  Diabetes  y Enfer-
edades Metabólicas  Asociadas  (Web Center for Biomedical
esearch in Diabetes and Associated Metabolic Diseases), Insti-
uto de  Salud  Carlos  III  (Carlos III Health Institute), Madrid,
pain]. F.dZ. is a clinical investigator supported by the Clin-
cal Research Council of the Leuven University Hospitals.
.M.G. and F.V. are investigators for CIBEROBN [Centro  de
nvestigación  Biomédica  en  Red  Fisiopatología  de  la  Obesi-Please cite this article in press as: Díaz M, et al. Effects of ethinylestradiol–
FGF21 levels in adolescent girls with androgen excess. Diabetes Metab (2
ad y  Nutrición  (Web Center for Biomedical Research in
hysiopathology of Obesity and Nutrition)]. The study was
upported by a grant (PI09/90444) included in the National
 + D + I programme, co-sponsored by the Instituto  de  Saludarlos  III  Subdirección  General  de  Evaluación  y  Formento  de
a Investigación  Sanitaria  (General Subdirectorate of Evalua-
ion and Development of Health Research) and Fondo  Europeo
e Desarrollo  Regional  (FEDER; European Regional Develop-
ent Fund) in Madrid, Spain (PI09/90444), and by MINECO
SAF2014-55725).
ppendix  A.  Supplementary  data
Supplementary data (Table S1) associated with this arti-
le can be found, in the online version, at http://dx.doi.org/
0.1016/j.diabet.2015.10.004.
eferencescyproterone acetate vs. pioglitazone–flutamide–metformin on plasma
015), http://dx.doi.org/10.1016/j.diabet.2015.10.004
[1] Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Gal-
breath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest
2005;115:1627–35.
ARTICLE IN PRESS+ModelDIABET-724; No. of Pages 4
4  Meta
[
[
[
[
[
Received in revised form 25 September 2015 Research letter / Diabetes &
[2] Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The
effects of LY2405319, an FGF21 analog, in obese human subjects with
type 2 diabetes. Cell Metab 2013;18:333–40.
[3] Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier
JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state.
Diabetes 2010;59:2781–9.
[4] Ibán˜ez L, Ong KK, López-Bermejo A, Dunger DB, de Zegher F. Hyper-
insulinaemic androgen excess in adolescent girls. Nat Rev Endocrinol
2014;100:499–508.
[5] Gorar S, Culha C, Uc ZA, Dellal FD, Serter R, Aral S, et al. Serum fibroblast
growth factor 21 levels in polycystic ovary syndrome. Gynecol Endocrinol
2010;26:819–26.
[6] Sahin SB, Ayaz T, Cure MC, Sezgin H, Ural UM, Balik G, et al. Fibroblast
growth factor 21 and its relation to metabolic parameters in women with
polycystic ovary syndrome. Scand J Clin Lab Invest 2014;74:465–9.
[7] Olszanecka-Glinianowicz M, Madej P, Wdowczyk M, Owczarek A,
Chudek J. Circulating FGF21 levels is related to nutritional status and
metabolic but not hormonal disturbances in polycystic ovary syndrome.
Eur J Endocrinol 2015;172:173–9.
[8] Ibán˜ez L, Díaz M, Sebastiani G, Marcos MV, López-Bermejo A, de Zegher
F. Oral contraception vs insulin sensitization for 18 months in nonobese
adolescents with androgen excess: posttreatment differences in C-reactive
protein, intima-media thickness, visceral adiposity, insulin sensitivity, and
menstrual regularity. J Clin Endocrinol Metab 2013;98:E902–7.
[9] Gallego-Escuredo JM, Gómez-Ambrosi J, Catalan V, Domingo P, Giralt
M, Frühbeck G, et al. Opposite alterations in FGF21 and FGF19 levels
and disturbed expression of the receptor machinery for endocrine FGFs in
obese patients. Int J Obes (Lond) 2015;39:121–9.
10] Reinehr T, Karges B, Meissner T, Wiegand S, Fritsch M, Holl RW, et al.
Fibroblast growth factor 21 and fetuin-A in obese adolescents with and
without type 2 diabetes. J Clin Endocrinol Metab 2015:jc20152192 [Epub
ahead of print].
11] Bobbert T, Schwarz F, Fischer-Rosinsky A, Pfeiffer AF, Möhlig M, Mai
K, et al. Fibroblast growth factor 21 predicts the metabolic syndrome and
type 2 diabetes in Caucasians. Diabetes Care 2013;36:145–9.
12] Nygaard EB, Vienberg SG, Ørskov C, Hansen HS, Andersen B. MetforminPlease cite this article in press as: Díaz M, et al. Effects of ethinylestradiol–
FGF21 levels in adolescent girls with androgen excess. Diabetes Metab (2
stimulates FGF21 expression in primary hepatocytes. Exp Diabetes Res
2012;2012:465282.
13] Oishi K, Tomita T. Thiazolidinediones are potent inducers of Fibroblast
Growth Factor 21 expression in the liver. Biol Pharm Bull 2011;34:1120–1.bolism xxx (2015) xxx–xxx
14] Lomonaco R, Ortiz-Lopez C, Orsak B, Webb A, Hardies J, Darland C, et al.
Hepatology 2012;55:1389–97.
M. Díaz a,b,1
J.M. Gallego-Escuredo c,d,1
F. de Zegher e
F. Villarroya c,d
L. Ibán˜ez b,∗
a Endocrinology,  Hospital  Sant  Joan  de  Déu,  University  of
Barcelona,  Barcelona,  Spain
b Centro  de  Investigación  Biomédica  en  Red  de  Diabetes  y
Enfermedades  Metabólicas  Asociadas  (CIBERDEM),  ISCIII,
Madrid,  Spain
c Department  of  Biochemistry  and  Molecular  Biology,
and Institute  of  Biomedicine,  University  of  Barcelona,
08028  Barcelona,  Spain
d Centro  de  Investigación  Biomédica  en  Red  Fisiopatología  de
la Obesidad  y Nutrición  (CIBEROBN),  ISCIII,  Madrid,  Spain
e Department  of  Development  and  Regeneration,  University  of
Leuven,  Leuven,  Belgium
∗ Corresponding author. Endocrinology Unit, Hospital Sant
Joan de Déu, University of Barcelona, Passeig de Sant Joan de
Déu, 2, 08950 Esplugues, Barcelona, Spain.
Tel.: +34 93 280 4000x4424; fax: +34 93 203 3959.
E-mail address:  libanez@hsjdbcn.org (L. Ibán˜ez)
1 Joint first authors.
Received 10 July 2015cyproterone acetate vs. pioglitazone–flutamide–metformin on plasma
015), http://dx.doi.org/10.1016/j.diabet.2015.10.004
Accepted 4 October 2015
